当前位置： SCI文献检索 > BMC Medical Genomics期刊下所有文献 > Pharmacogenetic testing through the direct-to-consumer genetic testing company 23andMe.

Pharmacogenetic testing through the direct-to-consumer genetic testing company 23andMe.

Abstract：

BACKGROUND:Rapid advances in scientific research have led to an increase in public awareness of genetic testing and pharmacogenetics. Direct-to-consumer (DTC) genetic testing companies, such as 23andMe, allow consumers to access their genetic information directly through an online service without the involvement of healthcare professionals. Here, we evaluate the clinical relevance of pharmacogenetic tests reported by 23andMe in their UK tests. METHODS:The research papers listed under each 23andMe report were evaluated, extracting information on effect size, sample size and ethnicity. A wider literature search was performed to provide a fuller assessment of the pharmacogenetic test and variants were matched to FDA recommendations. Additional evidence from CPIC guidelines, PharmGKB, and Dutch Pharmacogenetics Working Group was reviewed to determine current clinical practice. The value of the tests across ethnic groups was determined, including information on linkage disequilibrium between the tested SNP and causal pharmacogenetic variant, where relevant. RESULTS:23andMe offers 12 pharmacogenetic tests to their UK customers, some of which are in standard clinical practice, and others which are less widely applied. The clinical validity and clinical utility varies extensively between tests. The variants tested are likely to have different degrees of sensitivity due to different risk allele frequencies and linkage disequilibrium patterns across populations. The clinical relevance depends on the ethnicity of the individual and variability of pharmacogenetic markers. Further research is required to determine causal variants and provide more complete assessment of drug response and side effects. CONCLUSION:23andMe reports provide some useful pharmacogenetics information, mirroring clinical tests that are in standard use. Other tests are unspecific, providing limited guidance and may not be useful for patients without professional interpretation. Nevertheless, DTC companies like 23andMe act as a powerful intermediate step to integrate pharmacogenetic testing into clinical practice.

journal_name

BMC Med Genomics

journal_title

BMC medical genomics

authors

Lu M,Lewis CM,Traylor M

doi

10.1186/s12920-017-0283-0

subject

Has Abstract

pub_date

2017-06-19 00:00:00

pages

issue

issn

1755-8794

pii

10.1186/s12920-017-0283-0

journal_volume

pub_type

杂志文章

在线工具

Pharmacogenetic testing through the direct-to-consumer genetic testing company 23andMe.